3188
Y. Jiang et al. / Tetrahedron: Asymmetry 9 (1998) 3185–3189
3.2. Preparation of 1,6-bis(2,20-bisphenoxyphosphinoxy)spiro[4.4]nonane, L1
2,20-Dihydroxybiphenyl (600 mg, 3.2 mmol) dried under reduced pressure at 80°C for 30 min was
dissolved in benzene (10 ml) and pyridine (0.5 ml). This solution was added dropwise to a cooled
solution (0°C) of PCl3 (0.3 ml) and pyridine (0.5 ml). The reaction mixture was stirred for 6 h at 60°C.
The solvent and excess of PCl3 were removed under vacuum. The last trace of PCl3 in the residue
was removed by benzene (3 ml) under reduced pressure and this procedure was repeated three times.
Compound 2a formed in situ was dissolved in benzene (10 ml) and pyridine (1.0 ml). (1S,5S,6R)-
(cis,trans)-Spiro[4.4]nonane-1,6-diol (210 mg, 1.3 mmol) dissolved in benzene was added dropwise to
the solution of compound 2a at 0°C. The reaction mixture was stirred overnight at room temperature.
The resulting pyridine salts were filtered off. Evaporation of the solvent gave a white plaster which
was purified by flash column chromatography using toluene as eluent. A white foam (460 mg, 58%)
was obtained. [α]D20=−8.4 (0.35, CH2Cl2); mp=58–59°C; 31P-NMR (CD3COCD3, δ) 145.72, 140.69
ppm; 1H-NMR (CD3COCD3, δ) 7.56–7.20 (m, 16H), 4.97 (m, 1H), 4.38 (m, 1H), 2.07–1.47 (m, 12H).
Elemental analysis, calcd: C, 67.82; H, 5.14. Found: C, 67.71; H, 5.15.
3.3. Preparation of 1,6-bis(4,40,6,60-tetra-tert-butyl-2,20 -bisphenoxyphosphinoxy)spiro[4.4]nonane, L2
Treatment of 4,40,6,60-tetra-tert-butyl-2,20 -bis(phenol) (950 mg, 2.3 mmol) and (1S,5S,6R)-(cis,trans)-
spiro[4.4]nonane-1,6-diol (120 mg, 0.77 mmol) as described for compound L1 afforded compound L2
(380 mg, 48%). [α]D20=−15.6 (0.52, CH2Cl2); mp=139–140°C; 31P-NMR (CD3COCD3, δ) 146.59,
144.90 ppm; 1H-NMR (CD3COCD3, δ) 7.50–7.45 (m, 4H), 7.23–7.17 (m, 4H), 4.92 (m, 1H), 4.39 (m,
1H), 1.71–0.83 (m, 84H). Elemental analysis, calcd: C, 75.33; H, 9.07. Found: C, 75.59; H, 9.17
3.4. Preparation of 1,6-bis(6,60-di-tert-butyl-4,40 -dimethoxy-2,20-bisphenoxyphosphinoxy)spiro[4.4]-
nonane, L3
Treatment of 6,60-di-tert-butyl-4,40 -dimethoxy-2,20-bis(phenol) (900 mg, 2.5 mmol) and (1S,5S,6R)-
(cis,trans)-spiro[4.4]nonane-1,6-diol (130 mg, 0.83 mmol) as described for compound L1 afforded
compound L3 (510 mg, 66%). [α]D20=+13.8 (0.44, CH2Cl2); mp=81–82°C; 31P-NMR (CD3COCD3,
δ) 145.83, 144.81 ppm; 1H-NMR (CD3COCD3, δ) 6.96–6.93 (m, 4H), 6.83–6.76 (m, 4H), 4.93 (m, 1H),
4.41 (m, 1H), 3.84 (s, 6H), 3.82 (s, 6H), 1.82–0.83 (m, 48H). Elemental analysis, calcd: C, 68.52; H,
7.29. Found: C, 69.22; H, 7.64.
3.5. General procedure for the asymmetric hydroformylation
The autoclave filled with Rh(acac)(CO)2 (0.0085 mmol) and diphosphite (0.025 mmol) was purged
three times with syn gas (CO:H2=1:1), then toluene (1.5 ml) was added and pressurised to 10 atm of syn
gas. The reaction mixture was stirred for 10 h at 40°C to form the active catalyst. Styrene (4.25 mmol) and
toluene (1 ml) were placed in the autoclave and the syn gas was introduced until the desired pressure was
reached. After the desired reaction time, the autoclave was cooled to room temperature and depressurised.
cis-Decahydronaphthalene as an internal standard was added. The mixture was filtered on silica gel and
the filtrate was analysed by GC for the yield and regioselectivity. A sample of the filtrate was oxidised to
acid by Jones oxidation and analysed by GC for determination of the enantiomeric excess.